Case study / TYBR Health

You just got FDA clearance. Now the real work starts.

Post-clearance is when MedTech brands suddenly need content in every direction. Here is how TYBR Health turned that moment into a launch-ready creative system.

TYBR Health B3 Gel System campaign creative

B3 Gel System FDA cleared product creative

B3 Gel System surgery statistic creative

B3 Gel System clinical education creative

TYBR Health mobility campaign creative

The post-clearance scramble

Clearance was hard. Now you have to take it to market.

FDA clearance is a massive milestone. The next challenge is translating that achievement into the content system a launch actually needs.

Teams have to explain the mechanism, support clinical conversations, equip sales and distribution, keep investors aligned, and show up consistently across every market-facing channel. The need is not one asset. It is a whole library.

01

MOA animation

A clear mechanism-of-action story that shows how the product works, what makes it different, and why the science matters.

02

Presentations

Sales decks, investor updates, distributor presentations, and clinical education slides that keep the launch story consistent.

03

Social media rollout

Launch announcements, product education posts, clinical proof points, and ongoing content that keeps the market aware.

04

Email marketing

Announcement emails, nurture sequences, conference follow-ups, and sales-support messages for different audience segments.

05

Event materials

Booth graphics, leave-behinds, posters, presentation loops, and quick-hit materials that help the team show up prepared.

06

Clinical documents

Evidence summaries, product one-pagers, use-case explainers, and review-ready materials for clinical conversations.

The TYBR story

How TYBR built the content arsenal to support their product launch.

ClientTYBR Health

ProductB3 Gel

EngagementLaunch content ecosystem

TYBR Health B3 Gel System business card creative

B3 Gel System product poster creative

TYBR Health product brochure creative

B3 Gel System square clinical creative

TYBR Health product card creative

B3 Gel System clinical performance study creative

The build model

Start with the story. Build the library. Launch with everything aligned.

Every launch starts in a slightly different place. For TYBR, the first anchor was a 90-second motion animation that could explain B3 Gel clearly and give the team a shared story to build from.

01

Start with the story

The animation helped translate the clinical problem, mechanism, product value, and launch narrative into one clear sequence.

02

Build the library

From that source asset, we created product renderings, still frames, mechanism visuals, and clinical graphics the team could reuse everywhere.

03

Launch aligned

That library made the website, sales and marketing materials, clinical brochures, and other launch assets faster and more consistent to produce.

How this works

Turning one anchor story into a launch library.

A short walkthrough on starting with a larger source asset, then extracting the visual and strategic pieces that make the website, sales materials, and clinical education easier to build.

Client response

In TYBR's words.

All testimonials →

The Vuelab team have been true partners in this process. They didn't just execute our vision - they enhanced it with their experience and creative approach. The assets they've created will be central to our launch strategy and ongoing marketing efforts.

Chris Wright

VP of Business Development, TYBR Health

Chris Wright

The Vuelab team truly understood what we were trying to accomplish with our B3 GEL™ visualization. They took our scientific concepts and translated them into sophisticated, modern visuals that will resonate with surgeons while maintaining the scientific integrity we needed.

Ian Dawson

Strategic Marketing, TYBR Health

Ian Dawson

Turn clearance into a launch-ready content system.

Give us a few minutes, and we'll show you how to better visualize your product.

Have a question instead?
Send us a note.